417 Biochemical disease-free and overall survival of treatments for localized prostate cancer: Cohort study with a 7 year follow-up

2014 ◽  
Vol 13 (1) ◽  
pp. e417
Author(s):  
X. Bonet ◽  
J.F. Suárez ◽  
M. Castells ◽  
A.J. Vicéns ◽  
E. Franco ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Cohort Study ◽  
Localized Prostate Cancer ◽  
Disease Free

MP45-03 BIOCHEMICAL DISEASE-FREE AND OVERALL SURVIVAL OF TREATMENTS FOR LOCALIZED PROSTATE CANCER: COHORT STUDY WITH A 7 YEAR FOLLOW-UP

2014 ◽  
Vol 191 (4S) ◽  
Author(s):  
Xavier Bonet Puntí ◽  
Jose Francisco ◽  
Suarez Novo ◽  
Manel Castells Esteve ◽  
Andrew John ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Cohort Study ◽  
Localized Prostate Cancer ◽  
Disease Free

125I Brachytherapy for Localized Prostate Cancer: A Single Institution Experience

2013 ◽  
Vol 99 (1) ◽  
pp. 83-87 ◽  
Author(s):  
Alessia Guarneri ◽  
Angela Botticella ◽  
Andrea Riccardo Filippi ◽  
Fernando Munoz ◽  
Giancarlo Beltramo ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Multivariate Analysis ◽  
Early Stage ◽  
Disease Free Survival ◽  
Localized Prostate Cancer ◽  
Free Survival ◽  
Genitourinary Toxicity ◽  
Grade 3 ◽  
Disease Free

Aims and background To evaluate the clinical outcome of a cohort of localized prostate cancer patients treated with 125I permanent brachytherapy at the University of Turin. Methods and study design A retrospective analysis was carried out on 167 consecutive patients with early stage prostate adenocarcinoma who underwent 125I brachytherapy between January 2003 and December 2010. A minimum follow-up of ≥12 months was mandatory for inclusion. Biochemical disease-free survival (defined on the basis of the ASTRO definition and the ASTRO-Phoenix definition) was chosen as the primary end point. Secondary end points were gastrointestinal and genitourinary toxicity (acute and late, defined according to the RTOG scale). Results With a median follow-up of 42 months (range, 13.5–90.7), biochemical disease-free survival at 3 and 5 years was respectively 91.1% and 85.7%, according to the ASTRO definition and 94.5% and 85.1% according to ASTRO-Phoenix definition (for statistical purposes, only the ASTRO definition was used). Hormone treatment and nadir PSA (cutoff of 0.35 ng/ml) were the only factors affecting biochemical disease-free survival both on univariate ( P = 0.02 and P = 0.001, respectively) and multivariate analysis (HR 0.024; P = 0.021 and HR 21.6; P = 0.006, respectively). Only 3.6% of patients experienced ≥grade 3 acute urinary toxicity and 5% ≥grade 3 late urinary toxicity. Prior transurethral prostate resection was the only independent predictor of grade 3 late urinary toxicity on multivariate analysis (HR 0.13; P = 0.009). Conclusions This mono-institutional series confirmed that brachytherapy is an effective and safe treatment modality for localized prostate cancer, with acceptable short- and long-term morbidity rates.

Quality of life impact of treatments for localized prostate cancer: Cohort study with a 5year follow-up

2013 ◽  
Vol 108 (2) ◽  
pp. 306-313 ◽  
Author(s):  
Montse Ferrer ◽  
Ferran Guedea ◽  
José Francisco Suárez ◽  
Belén de Paula ◽  
Víctor Macías ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Cohort Study ◽  
Localized Prostate Cancer ◽  
Life Impact

scholarly journals Disease-free survival (DFS) as a surrogate for overall survival (OS) in localized prostate cancer (CaP).

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 5023-5023 ◽  
Author(s):  
Christopher Sweeney ◽  
Wanling Xie ◽  
Meredith M. Regan ◽  
Mari Nakabayashi ◽  
Marc E. Buyse ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Disease Free Survival ◽  
Localized Prostate Cancer ◽  
Free Survival ◽  
Disease Free

Oncologic outcomes of radiation therapy following active surveillance for low- and intermediate-risk localized prostate cancer.

2017 ◽  
Vol 35 (6_suppl) ◽  
pp. 42-42
Author(s):  
Ardalan Ahmad ◽  
Melvin Chua ◽  
Jure Murgic ◽  
Hamid Reza Raziee ◽  
Ali Hosni ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Active Surveillance ◽  
Survival Rates ◽  
Intensity Modulated Radiotherapy ◽  
Localized Prostate Cancer ◽  
Oncologic Outcomes ◽  
Biochemical Relapse ◽  
Curative Intent

42 Background: To evaluate the oncologic outcomes and potential impact of delayed radical treatment in the form of radiotherapy (RT), in men with localized prostate cancer progressing after active surveillance (AS). Methods: We identified patients on AS subsequently treated with state-of-the-art RT (either dose-escalated image-guided intensity modulated radiotherapy [IG-IMRT] or low-dose-rate brachytherapy [LDR-BT]). Based on the clinical characteristics at time of AS progression, we compared the oncologic outcomes to matched patients treated with upfront RT after diagnose. One to two matching patients per AS case were identified from existing RT databases based on: age (+/- 3 years), clinical prognostic factors (NCCN risk group; PSA +/- 2ng/mL; cT category; primary and secondary Gleason score; percentage of diagnostic cores involved dichotomized at < or > 50%), and treatment modality (IG-IMRT or LDR-BT). We aimed to determine whether patients on AS have potentially compromised outcomes. Results: We identified 215 patients (out of 1070 AS cohort) undergoing RT after a median of 26 months (IQR 16-52.5) on AS. Median follow-up post RT was 4.8 years (IQR 2.9-7.2). No patient died of prostate cancer. At 5-years, the biochemical relapse free-, metastases free- and overall-survival rate were respectively 98.6%, 99.1%, 98.6% in the AS cohort. Matched cohort comprised 400 patients treated with IG-IMRT (71%) or LDR-BT (29%). Adequate matching was confirmed. The median follow-up post RT was 8.2 years (IQR 4.7-10). At 5-years, biochemical relapse free-, metastases free- and overall-survival rates of 98.5%, 98.7%, 93.7% respectively, which were not statistically different compared to those patients treated upon AS progression. Conclusions: Curative-intent radiotherapy (i.e. dose-escalated IG-IMRT or LDR-BT) after a period of AS renders excellent oncologic outcomes at 5 years. Moreover, the delay of therapy after a period of AS does not appear to result in inferior oncologic outcomes compared to patients with similar risk characteristics undergoing upfront radical radiotherapy.

Impact of age at diagnosis on overall and disease-free survival in men with prostate cancer following conformal 3D radiation therapy

2012 ◽  
Vol 98 (6) ◽  
pp. 722-727 ◽  
Author(s):  
Angelo Maggio ◽  
Rocco Panaia ◽  
Elisabetta Garibaldi ◽  
Sara Bresciani ◽  
Giuseppe Malinverni ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Radiation Therapy ◽  
Disease Free Survival ◽  
Age At Diagnosis ◽  
Conformal Radiation Therapy ◽  
Free Survival ◽  
3D Conformal Radiation Therapy ◽  
Disease Free

Aims and background The impact of age on prostate cancer outcome has been controversial. The aim of the study was to evaluate the role of age on overall survival and disease-free survival in patients affected by prostate cancer when treated with 3D conformal radiation therapy. Methods and study design From 1999 to 2005, 1002 patients with T1–T3 prostate cancer were treated with 3D conformal radiation therapy, delivering a median dose of 75.6, 66.6 and 45 Gy to the prostate, seminal vesicles and pelvic nodes (if necessary), respectively. Patients were divided into four groups (<65, 65–70, 70–75, >75 years) according to age at diagnosis. The relationship between age and both overall survival and disease-free survival was calculated with Kaplan-Meier analysis and the comparison between curves was performed by the logrank test. ROC analysis allowed assessment of the best age cutoff. Results Mean age was 71 ± 6 years (median, 72). Median and mean follow-up was 71.4 and 69 months, respectively. In multivariate analysis, there was no significant difference in the distribution of disease risk between age groups. Analysis demonstrated that older age is a strong positive predictor of survival (odds ratio for stratified patients older than 70 years was <1). In fact, at the 90 month follow-up, overall survival and disease-free survival varied with age, increasing from 85% to 95% and from 78% to 94%, respectively. ROC curve analysis yielded a cutoff age value discriminating overall survival and disease-free survival of 72 years. Conclusions Age is a strong positive predictor of overall survival and disease-free survival, playing a protective role for stratified patients up to 72 years of age.

scholarly journals Radical radiotherapy for localized prostate cancer in elderly

2005 ◽  
Vol 52 (4) ◽  
pp. 103-107
Author(s):  
S. Stojanovic ◽  
Lj. Radosevic-Jelic ◽  
C. Tulic ◽  
I. Popov ◽  
D. Babic ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Overall Survival ◽  
Elderly Patients ◽  
Local Control ◽  
High Energy ◽  
Definitive Treatment ◽  
Low Grade ◽  
Radical Radiotherapy ◽  
Disease Free

Background: Prostate cancer is an age related neoplasm, with high incidence in the group of elderly man. The correct management must to be balanced between the benefits of the treatment and its disadvantages. Radiotherapy as definitive treatment is commonly reserved for older patients and patients with high surgical risk and is widely used as a treatment of choice. Aim: The aim of this study was to determine the role of radical radiotherapy for localized prostate carcinoma in patients 70 years age or older concerning treatment morbidity, local control, disease free and overall survival. Material and methods: A clinical prospective non-randomized study was performed including 103 elderly patients with an age 70 or above, between January 1991 and April 2005, at the Institute for Oncology and Radiology of Serbia. Median age of patients was 74,89 years (range 70- 80 years). Stage distribution was as follows: stage A - 3 patients (2.9 %), stage B - 69 patients (67%) and stage C - 31 patients (30. l%). Out of 103 patients, initial PSA value was noted in 87 patients. The mean value of initial PSA was 18,06 ng/ml. Radical radiotherapy was conducted on megavoltage linear accelerators with high energy photons (10, 18 MeV) and total tumor dose of 65 Gy. Results: Low grade acute complications were registered in 70 patients (65%). Mean follow up time was 40, 13 months. The disease outcome at the last follow up show that 79 patients (76.7%) had no evidence of disease and 24 patients (23.3%) relapsed. Overall survival rates were 65, 29% and 44, 52% and disease free survival 66, 59% and 63, 26% at 5 and 10 years. Disease specific survival was at 5 and 10 years 73,32% and 65, 42% respectively. Late sequels (gradus I and II) are registered in 22 patients (21.36%), out of 103. Conclusion: Radical radiotherapy for localized carcinoma of the prostate is effective treatment option in elderly patients with good local control, present treatment tolerance providing good quality of life and long term cure.

Sign in / Sign up

Export Citation Format

Share Document